AstraZeneca Aiming To Extend Brilinta Use In PCI patients
Executive Summary
AstraZeneca PLC’s newer oncology treatments are currently powering its growth, but the company is also looking to its cardiovascular, renal & metabolism (CVRM) portfolio to contribute, and a new study of Brilinta will help.
You may also be interested in...
Keeping Track: Industry Beefs Up 2020 Review Pipeline With Submissions Galore
The latest drug development news and highlights from our US FDA Performance Tracker.